BBS-Bioactive Bone Substitutes has resolved on a share

BBS-Bioactive Bone Substitutes Oyj, Company launch, 4 November 2022 at 9.50 EET

The Company’s Board of Directors has determined on November 4th 2022 to concern 275,000 shares with out consideration to the corporate itself, for potential mortgage conversions in addition to for different potential functions, in accordance with authorisation from the Extraordinary Shareholders Meeting in 17 March, 2022.

After the direct concern, 509 523 treasury shares are within the possession of BBS, representing roughly 5,1 % of the overall shares and votes of the corporate.

For extra info:

Ilkka Kangasniemi, CEO,
tel. +358 40 708 0307, e-mail: [email protected] 

Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, [email protected] 

BBS in short

BBS-Bioactive Bone Substitutes is a well being expertise firm that began operations in 2003. We have developed a new product for the remedy of extreme bone fractures and lumber issues. Our aim is to supply a new technology of medical merchandise for the remedy of bone injury in orthopaedic surgical procedure. In the pharmaceutical sector, growth and analysis requires perseverance and braveness to develop new issues. We have proof of this for over 20 years. Our actions are characterised by prime experience, innovation and workers who’re enthusiastic and dedicated to their work. The ARTEBONE ® within the closing levels of product growth, and we’re on the lookout for a CE marking that allows commercialisation within the EU. We are a firm in Oulu with a pharmaceutical manufacturing unit allow in Reisjärvi.

BBS-Bioactive Bone Substitutes Oyj:n shares are listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

More info: www.bbs-artebone.fi